top of page
Search


Imugene doses first patient in “hard to treat” cancer drug trial
Fresh from news of a “complete response” from other clinical trials last week, Imugene (ASX: IMU) has now dosed the first patient with a...

Sheena Francis
Nov 11, 2024


Imugene launches first Aussie lymphoma cancer trial
Imugene’s launch of its Australian-first trials against diffuse large B-cell lymphoma blood cancer may provide an answer to some patients’ prayers. Credit: File In an Australian first, clinical cancer researcher and developer Imugene (ASX: IMU) will launch its first “azer-cel” clinical trial against a difficult-to-treat form of non-Hodgkins lymphoma at Sydney’s Royal Prince Alfred Hospital. Azer-cel is Imugene’s “allogeneic off-the-shelf CAR T-cell therapy” which targets a sp

Doug Bright
Nov 8, 2024


Imugene hails 2-year “complete response” in cancer trial
Imugene is celebrating more than two years’ “complete response” for one of its bile tract cancer trial therapy subjects in its CF33 MAST VAXINIA study. Credit: File Clinical-stage immuno-oncology company Imugene (ASX: IMU) is celebrating more than two years’ “complete response” for one of its bile tract cancer trial therapy subjects in its CF33 MAST VAXINIA study. The outcome validates a January conclusion regarding the subject who had then passed the 430 day CR response mark

Doug Bright
Nov 5, 2024


Imugene gets crucial FDA nod for bile tract cancer drug
Imugene has scored a prized FDA orphan drug approval to boost its fight against bile tract cancer. Credit: File Imugene (ASX: IMU) has landed a prized United States Food and Drug Administration (FDA) orphan drug approval for its bile tract cancer therapy following positive results from its recent metastatic advanced solid tumour (MAST) trials to treat the rare and insidious disease known as cholangiocarcinoma. The FDA has granted orphan drug designation (ODD) to the company’s

Craig Nolan
Sep 18, 2024


Early trial results leave Imugene patients cancer-free
Imugene has reported promising results from its phase-1b clinical trials aimed at tackling blood cancer. Credit: File The first two blood cancer patients taking part in a United States-based trial, who had suffered relapses despite having treatment, have now been in remission for up to 120 days after being dosed with Imugene’s (ASX: IMU) azer-cel therapy. In new results that the company says suggest “improved outcomes”, the patients have remained cancer-free for 120 days and

Andrew Todd
Sep 2, 2024


Imugene delivers first Aussie bile tract cancer trial dose
Imugene has launched its latest trial for its cancer-killing “VAXINIA” therapy that is designed to combat bile tract cancer. Credit: File Imugene (ASX: IMU) has dosed its first of 10 Australian patients with its potent “VAXINIA” therapy as part of its phase-one bile tract cancer trial being conducted at St Vincent’s Hospital in Melbourne. The trial is aimed at proving the therapy’s ability to kill off the difficult-to-treat insidious disease that forms in the body’s bile duct

Craig Nolan
Jul 10, 2024


Imugene delivers first combo dose in bile tract cancer study
Imugene has delivered the initial combination dose in a world-first clinical cancer trial. Credit: File Imugene (ASX: IMU) has confirmed the delivery of its first “onCARlytics” combination therapy dose to a bile duct cancer patient in the initial phase of a world-first trial at the City of Hope medical centre in the United States. The dose delivered to the patient living with the condition also known as “cholangiocarcinoma” – a rare and aggressive cancer that originates in th

Doug Bright
Jun 24, 2024


Imugene cancer fight bolstered by strategic US partnership
Imugene has secured a strategic manufacturing deal with Kincell Bio. Credit: File Australian anti-cancer company Imugene (ASX: IMU) has stamped a strategic manufacturing and processing agreement with Kincell Bio, with the latter agreeing to purchase the company’s United States-based facility for US$6 million (AU$9.34 million). Under the deal, Kincell will cough up the cash in both upfront and milestone-driven payments over three years to acquire Imugene’s North Carolina Curre

Helen Barling
Apr 16, 2024


Imugene launches pivotal bile tract cancer expansion study
Imugene’s MAST trial is showing positive results on patients suffering from gastrointestinal cancers. Credit: File ASX-listed medical technology company Imugene (ASX: IMU) has launched a pivotal expansion study targeting patients with bile tract cancer, also known as cholangiocarcinoma, following encouraging early results from its Metastatic Advanced Solid Tumours (MAST) trial. Cholangiocarcinoma is a rare and aggressive cancer that originates in the bile ducts and typically
Steve Butler
Apr 15, 2024


Imugene locks down cancer patent in massive Chinese market
Imugene has received patent protection for its cancer treatment in China. Credit: File Australian anti-cancer company Imugene (ASX: IMU) has received a patent to protect its unique cancer treatment in China – the largest and most lucrative pharmaceutical market in Asia. The patent protects the method of composition and use of its licensed oncolytic virotherapy in China up to 2037 and follows previous grants in both Japan and South Korea. Imugene’s “oncolytic virotherapy” know
Michael Philipps
Apr 4, 2024


Imugene to tackle cancer tumours with combo treatment
ASX-listed Imugene will move onto the combination phase of its clinical trial to treat tumours. Credit: File Imugene (ASX: IMU) has cleared the first hurdle in its clinical trial to test the safety and efficacy of its “onCARlytics” treatment for solid tumours after receiving the green light to advance to the combination phase. Management says the trial’s Cohort Review Committee observed no safety issues in the onCARlytics single therapy lead-in study and recommended opening t
Michael Philipps
Mar 11, 2024


Imugene advances search-and-destroy cancer mission
Imugene has added the first patient with bile tract cancer to its ongoing clinical trial in the United States. Credit: File An Australian-based medical mission to flesh out and kill cancerous cells in humans has received a boost after ASX-listed medtech Imugene intravenously dosed its first patient diagnosed with bile tract cancer as part of a clinical trial. The patient, engaged in the intravenous monotherapy arm of the trial, was dosed at the City of Hope medical facility i
Michael Philipps
Feb 15, 2024


Imugene extends anti-cancer trial following recent successes
Imugene has extended its VAXINIA anti-cancer drug trial following recent successes Credit: File Following recent successes, Imugene has advanced its Phase 1 clinical study with the first Cohort 5 patients now receiving doses of the company’s novel potentially cancer-killing “CF33- hNIS” (VAXINIA) therapy. Imugene says Cohort 5 patient responses will be evaluated following their next monotherapy dose level by both intratumoural (IT) and intravenous (IV) delivery, with the firs

Doug Bright
Jan 19, 2024


Imugene to expand cancer treatment trial following early success
Imugene is closing on the elusive cure for some cancers Credit: File Clinical stage immune-oncology company Imugene has reported some eye-catching results in an update of its Phase 1 trial to assess the safety and efficacy of its cancer-killing CF33-hNIS Vaxinia therapy with one patient experiencing a “complete response” (CR) having now been in remission for over a year following intratumoural mid-strength dosing with Vaxinia. In initial trial cohorts whose tumours received d

Doug Bright
Jan 17, 2024


Imugene out to supercharge cancer patients in new alliance
Imugene’s research is providing hope for cancer patients. Credit: File Imugene has joined with United States-based NeoImmuneTech (NIT) for a two-year collaboration aimed at combining their respective therapies to “supercharge” the T cells of cancer patients in a mission to kill the deadly disease. The pre-clinical studies will be designed to assess the potential for NIT’s proprietary immune T-cell amplifier “NT-17” to increase the cancer-fighting properties in a patient’s own

Doug Bright
Dec 12, 2023


Imugene on brink of European patent for cancer drug
Imugene is set to kick off a clinical trial for its PD1-Vaxx cancer treatment next year. Credit: File Imugene expects to secure a crucial patent for its “PD1-Vaxx” lung cancer vaccine from the European Patent Office this month, with a trial also set for next year to test the drug’s treatment of colorectal cancer (CRC). PD1-Vaxx is currently in the development stage of a bid to target non-small cell lung cancer (NSCLC), while with the CRC trial will be run across six sites in
Michael Philipps
Dec 6, 2023


Imugene cancer virus earns crucial FDA fast-track status
Imugene is bringing hope to families with its cancer-fighting mission. Credit: File The US Food and Drug Administration has stamped Imugene’s “Vaxinia” drug trials aimed at treating bile duct cancer with “fast-track” status, providing the company with a suite of crucial review and approval priorities. The status designation will allow Imugene to collaborate more closely with the powerful FDA and puts it near the top of the list for future FDA reviews. It relates to the compan

Doug Bright
Nov 28, 2023


Cancer-fighting mission shoots Imugene up ASX boards
Cancer. In modern days of fast vehicles and seemingly even faster living, there are few people or families who have not been touched by some form of the insidious disease. From the breast to the brain, or the kidneys to the ovaries, the bastard thing seems to be almost everywhere. But there is hope – and thankfully, companies such as Imugene are trying desperately and cleverly to give us all more if it. And the company’s multi=pronged mission aimed at beating cancer is clearl

Andrew Todd
Nov 13, 2023


Holy grail cancer treatment one step closer for Imugene
Imugene continues to boost hope for families affected by cancer. Credit: File Imugene has continued to set the ASX boards alight after revealing it had delivered the first dose of its azer-cel therapy to a patient suffering from “difficult-to-treat” diffuse large B-cell lymphoma (DLBCL) in the United States. The company’s stock has risen nearly 285 per cent in less than three weeks as it continues to conduct a range of trials aimed at beating the scourge that is cancer. Manag

Doug Bright
Nov 10, 2023


Hope grows with positive signals in Imugene cancer trial
Imugene has recorded early positive signals from trials evaluating its cancer-killing virus. Credit: File Australian immune-oncology company Imugene has recorded positive early signals from the first phase of its metastatic advanced solid tumour (MAST) clinical trial evaluating the safety and efficacy of its novel cancer-killing virus known as “Vaxinia” (CF33-hNIS). The news comes hot on the heels of the company’s revelations last week that it had cleared the fourth cohort of

Helen Barling
Nov 6, 2023
bottom of page